Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits. We evaluated the efficacy and safety of rapid, peripheral, high-dose cyclophosphamide (TurboCy) in 15 patients intending to proceed with CAR T-cell therapy, BsAbs, or long-term regimens. The overall response rate was 80% and the clinical benefit rate was 100% in a heavily pretreated high-risk cohort. Cytopenias were common but no deaths occurred during bridging. All patients proceeded to their next line of intended therapy. TurboCy is an effective and safe bridging strategy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647735 | PMC |
| http://dx.doi.org/10.1002/jha2.1039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
J Clin Oncol
January 2025
Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN.
Purpose: Melanoma as a subsequent malignant neoplasm has been described among childhood cancer survivors; however, the risk factors and long-term survival are not well understood.
Methods: We assessed incidence, risk factors, and outcomes for melanoma among participants in the Childhood Cancer Survivor Study cohort. Cumulative incidence and standardized incidence ratios (SIRs) were calculated, and multivariable Cox models were used to determine hazard ratios (HRs) and associated 95% CI for melanoma risk factors.
Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation.
Ann Clin Transl Neurol
December 2024
Transplant and Cell Therapy Program, Division of Hematology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
Objectives: Patients with refractory myasthenia gravis (MG) have few treatment options. Autologous hematopoietic stem cell transplantation (HSCT) has been used to treat immune diseases; however, its use in the treatment of MG is not broadly considered. Our objective is to report on the efficacy and safety of HSCT in refractory MG.
View Article and Find Full Text PDFPolyangiitis Overlap Syndrome: Polyarteritis Nodosa with Leukocytoclastic Vasculitis Associated with Left Ventricular Thrombus and Vocal Cord Palsy: A Case Report.
Oman Med J
July 2024
Department of Medicine, Faculty of Medicine, Royal College of Medicine, Universiti Kuala Lumpur, Perak, Malaysia.
Polyangiitis overlap syndrome (POS) is a systemic vasculitis characterized by overlapping features of more than one well-defined vasculitic syndrome. We present the case of a 38-year-old Malay man with progressive dyspnea and palpable purpura in his lower limbs. The diagnostic evaluation revealed right-sided segmental pulmonary consolidation with pleural effusion, systolic cardiac dysfunction with the presence of an intracardiac thrombus, and left vocal cord palsy secondary to laryngeal mononeuropathy.
View Article and Find Full Text PDFAseptic Meningitis and White Matter Disease in Childhood-Onset Neuropsychiatric Lupus.
Case Rep Rheumatol
December 2024
Department of Paediatrics, Queen Elizabeth Hospital, 30 Gascoigne Road, King's Park, Hong Kong.
We reported a 10-year-old girl who had an atypical demyelinating disease as the presentation of her neuropsychiatric lupus. The patient had a 4-year history of systemic lupus erythematosus which had been on remission until she presented with fever and headache at the age of 10 years. Physical examination showed meningism.
View Article and Find Full Text PDF[Anti-tumor effect of Inonotus obliquus extract on 4T1 tumor-bearing mice].
Wei Sheng Yan Jiu
November 2024
NHC Key Laboratory of Public Nutrition and Health, National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
Objective: To explore the antitumor effect of Inonotus obliquus extract on 4T1 tumor-bearing mice in vivo and its possible mechanism.
Methods: 4T1 tumor-bearing mice model was established. After successful modeling, tumor-bearing mice were randomly divided into model control group, cyclophosphamide(CTX) positive group, and high, medium and low dose groups of Inonotus obliquus extract, with 10 mice in each group, which were administered continuously for 21 days.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!